Table 2 Summary of major antibody–drug conjugates in R/R DLBCLs and NHLs
Medicine name | Targets | Study | Patients | Treatment | Responses |
|---|---|---|---|---|---|
Lonca | CD19 | Phase II LOTIS-2 trial (NCT03589469) | R/R DLBCL (NOS), HGBCL, PMBCL | Monotherapy | ORR/CRR: 48.3% (70/145)/24.1% (35/145) Median DOR/PFS/OS: 10.3/4.9/9.9 mo |
Phase II LOTIS-3 trial (NCT03684694) | Advanced DLBCL | Lonca plus ibrutinib | ORR/CRR in total: 57.1% (20/35)/34.3% (12/35) ORR/CRR in GCB: 76.9% (10/13)/46.2% (6/13) ORR/CRR in non-GCB: 45.5% (10/22)/27.3% (6/22) Median DOR: 5.49 mo (NR in both GCB and non-GCB) | ||
SAR3419 | CD19 | Phase II (NCT01472887) | R/R DLBCL | Monotherapy | ORR/CRR in total: 43.9% (18/41)/14.6% (6/41) ORR/CRR in refractory to last regimen: 26.7% (4/15)/6.7% (1/15) ORR/CRR in relapsed DLBCL: 53.8% (14/26)/19.2% (5/26) ORR/CRR in primary refractory: 21.4% (3/14)/7.1% (1/14) median DOR/PFS/OS: 4.7/4.4/9.2 mo |
BV | CD30 | Phase II (NCT01421667) | DLBCL, other B-cell NHL | Monotherapy | ORR/CRR in total DLBCL: 44% (21/44)/17% (8/48) ORR/CRR in refractory DLBCL: 44% (17/39)/15% (6/39) ORR/CRR in relapsed DLBCL: 38% (3/8)/25% (2/8) ORR/CRR in other B-cell NHL: 26% (5/19) 16% (3/19) |
Phase I (NCT02086604) | R/R DLBCL | BV plus Len | ORR/CRR in CD30+/GCB, 87.5% (7/8)/50% (4/8) ORR/CRR in CD30−/GCB, 25% (3/12)/17% (2/12) ORR/CRR in CD30+/non-GCB, 57% (4/7)29% (2/7) ORR/CRR in CD30−/non-GCB, 70% (7/10)/50% (5/10) median PFS/ OS in total, 10.2/14.3 mo | ||
Phase III (NCT04404283) | R/R DLBCL | BV plus R2 | Clinical trials ongoing | ||
Pina | CD22 | Phase II ROMULUS trial (NCT01691898) | R/R DLBCL R/R FL | R-Pina | ORR/CRR in R/R DLBCL, 60% (25/42)/26% (11/42) ORR/CRR in R/R FL, 62% (13/21)/5% (1/21) Median DOR/PFS/OS of R/R DLBCL, 6.2/5.4/16.5 mo Median DOR/PFS/OS of R/R FL, 6.5/12.7/NR mo |
Pola | CD79b | Phase II ROMULUS trial (NCT01691898) | R/R DLBCL R/R FL | R-Pola | ORR/CRR in R/R DLBCL, 54% (21/39)/21% (8/39) ORR/CRR in R/R FL, 70% (14/20)/45% (9/20) Median DOR/PFS/OS of R/R DLBCL, 13.4/5.6/20.1 mo Median DOR/PFS/OS of R/R FL, 9.4/15.3/NR mo |
Phase II DCDS4501A trial (NCT02257567) | R/R DLBCL R/R FL | Pola-BR vs. BR | Best responses (INV) ORR, 70% (28/40) vs. 32.5% (13/40) CRR, 57.5% (23/40) vs. 20% (8/40) Median DOR/PFS/OS: 10.3 VS. 4.1 mo/7.6 vs. 2.0 mo/12.4 vs. 4.7 mo | ||
Phase Ib/II (NCT02600897) | R/R DLBCL | Pola-R-Len | Best responses (INV) ORR/CRR, 74% (36/49)/35% (17/49) Median DOR/PFS/OS, 8.1/6.3/10.9 mo | ||
Phase Ib/II (NCT02611323) | R/R DLBCL | Pola-Ven-R | Best responses (INV) ORR/CRR, 65% (31/48)/38% (18/48) Median DOR/PFS/OS, 5.8/4.4/11.1 mon | ||
Phase III POLARGO trial (NCT04182204) | R/R DLBCL | Pola-R-GemOx vs. R-GemOx | Clinical trials ongoing |